Compare COKE & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COKE | HALO |
|---|---|---|
| Founded | 1902 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.5B | 14.8B |
| IPO Year | 1994 | 2001 |
| Metric | COKE | HALO |
|---|---|---|
| Price | $207.60 | $103.60 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $108.89 |
| AVG Volume (30 Days) | 492.0K | ★ 2.0M |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | ★ 0.47% | N/A |
| EPS Growth | ★ 156.81 | N/A |
| EPS | 1.21 | ★ 5.12 |
| Revenue | ★ $7,228,055,000.00 | $151,862,000.00 |
| Revenue This Year | N/A | $34.73 |
| Revenue Next Year | N/A | $11.71 |
| P/E Ratio | $168.74 | ★ $41.91 |
| Revenue Growth | ★ 4.76 | N/A |
| 52 Week Low | $136.97 | $61.23 |
| 52 Week High | $218.73 | $134.00 |
| Indicator | COKE | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 52.63 | 28.68 |
| Support Level | $179.77 | $64.08 |
| Resistance Level | $214.39 | $111.15 |
| Average True Range (ATR) | 8.77 | 4.39 |
| MACD | -0.58 | -2.09 |
| Stochastic Oscillator | 30.38 | 0.42 |
Coca-Cola Consolidated Inc distributes, markets, and manufactures nonalcoholic beverages. It offers a range of nonalcoholic beverage products and flavors, including both sparkling and still beverages. Sparkling beverages are carbonated beverages, and the Company's principal sparkling beverage is Coca-Cola. Still beverages include energy products and non-carbonated beverages such as bottled water, ready-to-drink tea, ready-to-drink coffee, enhanced water, juices, and sports drinks. The Company has two operating segments: Nonalcoholic Beverages and All Other. Key revenue is generated from Nonalcoholic Beverages.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.